AbCellera Biologics Inc. Common Shares ABCL
i
Market dataready · fetched 2026-11-04T04:37:39.294Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T00:59:33.871116391Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T04:37:38.912139+00:00
AbCellera Biologics Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.04 | 116.4% | 19.5% | |||
| 25Δ | 10.53 | 106.0% | 16.0% | |||
| 30Δ | 13.99 | 109.2% | 20.6% | 11.02 | 96.2% | 12.6% |
| 35Δ | 13.56 | 109.3% | 18.0% | 11.33 | 96.8% | 11.2% |
| 40Δ | 13.13 | 109.5% | 15.4% | 11.65 | 97.4% | 9.8% |
| 45Δ | 12.75 | 111.0% | 13.4% | 11.97 | 98.0% | 8.5% |
| 50Δ | 12.38 | 113.2% | 11.8% | 12.32 | 99.3% | 7.4% |
| 55Δ | 12.02 | 115.4% | 10.1% | 12.67 | 100.6% | 6.4% |
| 60Δ | 11.69 | 108.8% | 8.2% | 13.04 | 102.7% | 5.4% |
| 65Δ | 11.36 | 101.7% | 6.4% | 13.72 | 116.9% | 5.0% |
| 70Δ | 11.03 | 94.7% | 4.6% | 14.40 | 125.4% | 4.3% |
| 75Δ | 10.58 | 101.1% | 3.8% | 16.52 | 172.2% | 4.4% |
| 80Δ | 10.12 | 109.1% | 3.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.04
- IV
- 116.4%
- B/E move
- 19.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.53
- IV
- 106.0%
- B/E move
- 16.0%
30Δ
- Pseudo strike
- 13.99
- IV
- 109.2%
- B/E move
- 20.6%
- Pseudo strike
- 11.02
- IV
- 96.2%
- B/E move
- 12.6%
35Δ
- Pseudo strike
- 13.56
- IV
- 109.3%
- B/E move
- 18.0%
- Pseudo strike
- 11.33
- IV
- 96.8%
- B/E move
- 11.2%
40Δ
- Pseudo strike
- 13.13
- IV
- 109.5%
- B/E move
- 15.4%
- Pseudo strike
- 11.65
- IV
- 97.4%
- B/E move
- 9.8%
45Δ
- Pseudo strike
- 12.75
- IV
- 111.0%
- B/E move
- 13.4%
- Pseudo strike
- 11.97
- IV
- 98.0%
- B/E move
- 8.5%
50Δ
- Pseudo strike
- 12.38
- IV
- 113.2%
- B/E move
- 11.8%
- Pseudo strike
- 12.32
- IV
- 99.3%
- B/E move
- 7.4%
55Δ
- Pseudo strike
- 12.02
- IV
- 115.4%
- B/E move
- 10.1%
- Pseudo strike
- 12.67
- IV
- 100.6%
- B/E move
- 6.4%
60Δ
- Pseudo strike
- 11.69
- IV
- 108.8%
- B/E move
- 8.2%
- Pseudo strike
- 13.04
- IV
- 102.7%
- B/E move
- 5.4%
65Δ
- Pseudo strike
- 11.36
- IV
- 101.7%
- B/E move
- 6.4%
- Pseudo strike
- 13.72
- IV
- 116.9%
- B/E move
- 5.0%
70Δ
- Pseudo strike
- 11.03
- IV
- 94.7%
- B/E move
- 4.6%
- Pseudo strike
- 14.40
- IV
- 125.4%
- B/E move
- 4.3%
75Δ
- Pseudo strike
- 10.58
- IV
- 101.1%
- B/E move
- 3.8%
- Pseudo strike
- 16.52
- IV
- 172.2%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 10.12
- IV
- 109.1%
- B/E move
- 3.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 114.33% | |
| 96.35% | |
| 100.16% | |
| 93.66% | |
| 86.27% | |
| 91.47% | |
| 89.80% | |
| 87.72% | |
| 100.57% | |
| 92.95% | |
| 99.80% | |
| 116.58% | |
| 88.14% | |
| 85.96% | |
| 91.64% | |
| 88.52% | |
| 88.05% | |
| 84.68% | |
| 90.59% | |
| 83.85% | |
| 82.79% | |
| 83.75% | |
| 82.50% | |
| 87.19% | |
| 82.60% | |
| 82.67% | |
| 87.84% | |
| 89.18% | |
| 85.87% | |
| 89.38% | |
| 87.73% | |
| 88.59% | |
| 85.33% | |
| 84.64% | |
| 88.95% | |
| 92.02% | |
| 93.16% | |
| 92.27% | |
| 87.60% | |
| 82.89% | |
| 81.29% | |
| 78.46% | |
| 82.69% | |
| 80.79% | |
| 78.90% | |
| 84.55% | |
| 86.71% | |
| 83.40% | |
| 83.93% | |
| 83.56% | |
| 82.09% | |
| 77.09% | |
| 82.59% | |
| 81.85% | |
| 79.16% | |
| 84.47% | |
| 83.10% | |
| 86.45% | |
| 88.70% |
Biotechnology
ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus…
More →ABVX
Description unavailable
More →ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central…
More →